Thymalin vs Vesilute
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Thymalin is a polypeptide complex isolated from calf thymus glands (developed by the Russian Gerontology Institute), shown to restore immune function, extend lifespan, and reverse thymic involution. Clinical studies demonstrate improved immune parameters and up to 40% reduction in mortality in elderly patients.
- Vesilute is a tetrapeptide bioregulator (Lys-Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific for the retina and visual system. It supports retinal cell function, promotes normalization of photoreceptor protein synthesis, and is studied for age-related macular degeneration (AMD), retinal aging, and vision preservation in the elderly.
- Half-Life
- Not well characterized as a complex extract; individual peptides have varying kinetics
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- SubQ, IM
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 10 mg IM or SC daily
- 10 mg per day
- Frequency
- Once daily
- Daily for 10–30 days
- Key Benefits
- Restores thymic function and T-cell immunity
- Extends healthy lifespan (documented in long-term studies)
- Reduces infectious disease incidence in elderly
- Normalizes immune parameters in immunodeficiency
- Anti-tumor immune surveillance
- Improves vaccine response in elderly
- Reduces cardiovascular mortality (40% in landmark Russian study)
- Normalizes neuroendocrine function
- Supports retinal photoreceptor cell function and survival
- May slow progression of age-related macular degeneration
- Reduces retinal cell apoptosis from oxidative stress and aging
- Anti-aging effects on retinal pigment epithelium
- Potential support in diabetic retinopathy management
- Preserves visual acuity with aging
- Complementary to lutein, zeaxanthin, and NAD+ in ocular health protocols
- Side Effects
- Very well tolerated in decades of Russian clinical use
- Mild injection site reactions
- Rare: mild allergic reaction (natural extract)
- Transient flu-like symptoms on initiation (immune activation)
- Generally well tolerated
- Mild injection site reactions
- No significant ocular adverse events reported at standard doses
- Stacks With
- —
- —